XML 112 R93.htm IDEA: XBRL DOCUMENT v3.20.2
Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 28, 2020
Jun. 30, 2019
Jun. 28, 2020
Jun. 30, 2019
Revenue from External Customer [Line Items]        
Revenues [1] $ 11,801 $ 13,264 $ 23,829 $ 26,382
Biopharma, Upjohn And Consumer Healthcare Segments [Member]        
Revenue from External Customer [Line Items]        
Revenues 11,801 13,264 23,829 26,382
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Alliance revenues [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,404 1,187 2,786 2,277
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 289 217 578 396
Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]        
Revenue from External Customer [Line Items]        
Revenues [3] 1,237 1,218 2,644 2,455
Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 9,795 9,432 19,802 18,477
Internal Medicine [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 2,279 2,243 4,610 4,380
Internal Medicine [Member] | Biopharma [Member] | Eliquis [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 1,272 1,085 2,572 2,096
Internal Medicine [Member] | Biopharma [Member] | Chantix / Champix [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 235 276 505 549
Internal Medicine [Member] | Biopharma [Member] | Premarin family [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 152 193 304 361
Internal Medicine [Member] | Biopharma [Member] | BMP2 [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 57 79 127 145
Internal Medicine [Member] | Biopharma [Member] | Toviaz [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 64 65 124 125
Internal Medicine [Member] | Biopharma [Member] | All other Internal Medicine [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 498 544 978 1,103
Oncology [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 2,647 2,236 5,082 4,198
Oncology [Member] | Biopharma [Member] | Ibrance [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,349 1,261 2,598 2,394
Oncology [Member] | Biopharma [Member] | Xtandi alliance revenues [Member]        
Revenue from External Customer [Line Items]        
Revenues 266 201 475 369
Oncology [Member] | Biopharma [Member] | Sutent [Member]        
Revenue from External Customer [Line Items]        
Revenues 209 248 414 480
Oncology [Member] | Biopharma [Member] | Inlyta [Member]        
Revenue from External Customer [Line Items]        
Revenues 195 104 364 177
Oncology [Member] | Biopharma [Member] | Xalkori [Member]        
Revenue from External Customer [Line Items]        
Revenues 138 133 287 255
Oncology [Member] | Biopharma [Member] | Bosulif [Member]        
Revenue from External Customer [Line Items]        
Revenues 113 97 213 177
Oncology [Member] | Biopharma [Member] | Retacrit [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 87 51 176 82
Oncology [Member] | Biopharma [Member] | Braftovi [Member]        
Revenue from External Customer [Line Items]        
Revenues 36 0 74 0
Oncology [Member] | Biopharma [Member] | Mektovi [Member]        
Revenue from External Customer [Line Items]        
Revenues 32 0 69 0
Oncology [Member] | Biopharma [Member] | All other Oncology [Member]        
Revenue from External Customer [Line Items]        
Revenues 221 140 412 262
Hospital [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 1,794 1,838 3,807 3,665
Hospital [Member] | Biopharma [Member] | Sulperazon [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 102 165 289 342
Hospital [Member] | Biopharma [Member] | Medrol [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 78 120 207 240
Hospital [Member] | Biopharma [Member] | Zithromax [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 55 73 193 177
Hospital [Member] | Biopharma [Member] | Precedex [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 114 40 156 80
Hospital [Member] | Biopharma [Member] | Vfend [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 75 94 149 178
Hospital [Member] | Biopharma [Member] | Panzyga [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 63 44 136 61
Hospital [Member] | Biopharma [Member] | Zyvox [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 55 71 125 134
Hospital [Member] | Biopharma [Member] | Fragmin [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 58 63 118 123
Hospital [Member] | Biopharma [Member] | Pfizer CentreOne [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5],[6] 224 204 376 380
Hospital [Member] | Biopharma [Member] | All other Anti-infectives [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 367 420 811 825
Hospital [Member] | Biopharma [Member] | All other Hospital [Member]        
Revenue from External Customer [Line Items]        
Revenues [4],[5] 603 544 1,245 1,124
Vaccines [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,247 1,375 2,857 2,988
Vaccines [Member] | Biopharma [Member] | Prevnar 13/Prevenar 13 [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,116 1,179 2,566 2,665
Vaccines [Member] | Biopharma [Member] | Nimenrix [Member]        
Revenue from External Customer [Line Items]        
Revenues 56 58 130 107
Vaccines [Member] | Biopharma [Member] | All other Vaccines [Member]        
Revenue from External Customer [Line Items]        
Revenues 75 138 161 215
Inflammation and Immunology (I&I) [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 1,149 1,219 2,127 2,256
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Xeljanz [Member]        
Revenue from External Customer [Line Items]        
Revenues 635 613 1,086 1,036
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Enbrel (Outside the U.S. and Canada) [Member]        
Revenue from External Customer [Line Items]        
Revenues 337 420 684 871
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | Inflectra/Remsima [Member]        
Revenue from External Customer [Line Items]        
Revenues [2] 150 153 308 291
Inflammation and Immunology (I&I) [Member] | Biopharma [Member] | All other I & I [Member]        
Revenue from External Customer [Line Items]        
Revenues 26 34 48 59
Rare Disease [Member] | Biopharma [Member]        
Revenue from External Customer [Line Items]        
Revenues 681 521 1,319 991
Rare Disease [Member] | Biopharma [Member] | Vyndaqel/Vyndamax [Member]        
Revenue from External Customer [Line Items]        
Revenues 277 63 508 104
Rare Disease [Member] | Biopharma [Member] | BeneFIX [Member]        
Revenue from External Customer [Line Items]        
Revenues 109 121 230 247
Rare Disease [Member] | Biopharma [Member] | Genotropin [Member]        
Revenue from External Customer [Line Items]        
Revenues 106 125 209 232
Rare Disease [Member] | Biopharma [Member] | ReFacto AF/Xyntha [Member]        
Revenue from External Customer [Line Items]        
Revenues 91 108 181 214
Rare Disease [Member] | Biopharma [Member] | Somavert [Member]        
Revenue from External Customer [Line Items]        
Revenues 67 68 131 128
Rare Disease [Member] | Biopharma [Member] | All other Rare Disease [Member]        
Revenue from External Customer [Line Items]        
Revenues 31 35 61 66
Upjohn [Member] | Upjohn [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 2,006 2,970 4,027 6,184
Upjohn [Member] | Upjohn [Member] | Lipitor [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 431 407 836 1,029
Upjohn [Member] | Upjohn [Member] | Lyrica [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 349 1,175 706 2,362
Upjohn [Member] | Upjohn [Member] | Norvasc [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 222 216 419 516
Upjohn [Member] | Upjohn [Member] | Celebrex [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 139 174 295 347
Upjohn [Member] | Upjohn [Member] | Viagra [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 94 114 222 259
Upjohn [Member] | Upjohn [Member] | Effexor [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 86 86 163 163
Upjohn [Member] | Upjohn [Member] | Zoloft [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 79 73 157 143
Upjohn [Member] | Upjohn [Member] | EpiPen [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 64 67 136 123
Upjohn [Member] | Upjohn [Member] | Xalatan/Xalacom [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 65 72 126 133
Upjohn [Member] | Upjohn [Member] | All other Upjohn [Member]        
Revenue from External Customer [Line Items]        
Revenues [4] 476 587 968 1,109
Consumer Healthcare [Member] | Consumer Healthcare [Member]        
Revenue from External Customer [Line Items]        
Revenues [7] $ 0 $ 862 $ 0 $ 1,721
[1]
Amounts may not add due to rounding.
[2]
Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.
[3]
Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.
[4]
Beginning in 2020, Upjohn began managing our Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan for generic drugs in Japan (Mylan-Japan). As a result, revenues associated with our Meridian subsidiary, except for product revenues for EpiPen sold in Canada, and Mylan-Japan, are reported in our Upjohn business beginning in the first quarter of 2020. We have reclassified revenues associated with our Meridian subsidiary and Mylan-Japan from the Hospital and Internal Medicine categories to the Upjohn business to conform 2019 product revenues to the current presentation.
[5]
Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. Hospital also includes Pfizer CentreOne(d). All other Hospital primarily includes revenues from legacy Sterile Injectables Pharmaceuticals (SIP) products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in “All other Anti-infectives”.
[6]
Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements.
[7]
On July 31, 2019, Pfizer’s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK’s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see Note 2B.